Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Leases: 2021-2024

Historic Current Leases for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $42,000.

  • ARS Pharmaceuticals' Current Leases rose 471.57% to $583,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $583,000, marking a year-over-year increase of 471.57%. This contributed to the annual value of $42,000 for FY2024, which is 82.28% down from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Current Leases is $42,000, which was down 82.28% from $237,000 recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Current Leases ranged from a high of $237,000 in FY2023 and a low of $42,000 during FY2024.
  • Its 3-year average for Current Leases is $169,667, with a median of $230,000 in 2022.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Current Leases surged by 59.72% in 2022, and later crashed by 82.28% in 2024.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Current Leases stood at $144,000 in 2021, then soared by 59.72% to $230,000 in 2022, then rose by 3.04% to $237,000 in 2023, then plummeted by 82.28% to $42,000 in 2024.